FTXH Holdings — First Trust Nasdaq Pharmaceuticals ETF
All 51 reported holdings of First Trust Nasdaq Pharmaceuticals ETF (FTXH) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Johnson & Johnson | 7.45% | $2.17M |
| Bristol-Myers Squibb Company | 7.36% | $2.15M |
| Merck & Co., Inc | 7.36% | $2.15M |
| AbbVie Inc. | 7.10% | $2.07M |
| Eli Lilly & Co. | 6.62% | $1.93M |
| Pfizer Inc. | 3.85% | $1.12M |
| Regeneron Pharmaceuticals, Inc. | 3.74% | $1.09M |
| Biogen Inc | 3.62% | $1.06M |
| Gilead Sciences Inc. | 3.54% | $1.03M |
| Cardinal Health, Inc. | 3.49% | $1.02M |
| Amgen Inc. | 3.43% | $1.00M |
| Viatris Inc | 3.43% | $999.59K |
| Zoetis Inc. | 3.41% | $996.04K |
| Vertex Pharmaceuticals Incorporated | 3.40% | $992.66K |
| United Therapeutics Corporation | 3.31% | $966.56K |
| Incyte Corporation. | 2.21% | $644.06K |
| Jazz Pharmaceuticals PLC | 2.17% | $632.75K |
| Illumina Inc | 1.54% | $450.76K |
| Exelixis, Inc. | 1.51% | $440.87K |
| Medpace Holdings Inc. | 1.42% | $415.36K |
| PTC Therapeutics, Inc. | 1.27% | $371.24K |
| Charles River Laboratories International, Inc. | 1.26% | $366.91K |
| Biomarin Pharmaceutical Inc. | 1.22% | $356.90K |
| Neurocrine Biosciences Inc | 1.19% | $346.48K |
| Halozyme Therapeutics Inc | 1.11% | $323.47K |
| Alkermes PLC | 1.02% | $296.32K |
| Elanco Animal Health Inc | 0.90% | $261.44K |
| Spyre Therapeutics Inc | 0.61% | $178.20K |
| Protagonist Therapeutics Inc | 0.60% | $173.91K |
| TG Therapeutics Inc | 0.57% | $167.73K |
| Arrowhead Pharmaceuticals Inc | 0.56% | $163.71K |
| Catalyst Pharmaceuticals Inc. | 0.56% | $163.00K |
| Amneal Pharmaceuticals Inc | 0.55% | $161.39K |
| Arcus Biosciences, Inc. | 0.55% | $161.11K |
| Twist Bioscience Corporation | 0.53% | $153.87K |
| Ligand Pharmaceuticals Incorporated | 0.52% | $152.93K |
| Mirum Pharmaceuticals Inc. | 0.52% | $152.06K |
| Travere Therapeutics Inc | 0.52% | $151.52K |
| Alnylam Pharmaceuticals Inc. | 0.52% | $150.88K |
| Guardant Health Inc | 0.51% | $149.45K |
| Roivant Sciences Ltd | 0.50% | $145.43K |
| Moderna Inc | 0.49% | $144.07K |
| Supernus Pharmaceuticals, Inc | 0.49% | $143.49K |
| Krystal Biotech Inc | 0.49% | $142.33K |
| Tarsus Pharmaceuticals Inc | 0.48% | $141.14K |
| Ionis Pharmaceuticals, Inc. | 0.48% | $140.57K |
| 10X Genomics Inc | 0.48% | $139.93K |
| Kymera Therapeutics Inc | 0.47% | $138.51K |
| Acadia Pharmaceuticals Inc | 0.47% | $137.70K |
| Arcutis Biotherapeutics, Inc. | 0.45% | $132.71K |
| Dreyfus Government Cash Management Funds | 0.11% | $32.29K |
FTXH overview: performance, fees, allocation and SEC filings